Griffithsin

Last updated
Griffithsin
3ll2.png
Griffithsin in complex with a high-mannose branched carbohydrate. PDB 3ll2 [1]
Identifiers
Organism Griffithsia sp. (Red alga)
SymbolGRTF
PDB 3ll2 More structures
UniProt P84801

Griffithsin is a protein isolated from the red algae Griffithsia . It has a 121-amino acid sequence [2] which exhibits a Jacalin-like lectin fold. Several structures of this protein have been solved by X-ray crystallography and deposited in the PDB. It has been shown in vitro to be a highly potent HIV entry inhibitor. It is currently being investigated as a potential microbicide for use in the prevention of the transmission of HIV. [3]

Griffithsin shows a broad spectrum ability to bind to the glycoproteins of other viruses, such as the coronavirus. Griffithsin's three identical carbohydrate domains bind to specific oligosaccharides on the envelope of viral glycoproteins. This was demonstrated by in vitro and in vivo studies. [4] For instance, it was shown that griffithsin binds to the SARS-CoV spike glycoprotein to inhibit entry of the SARS virus and thus inhibit infection. A 2014 study showed griffithsin to also possess useful antiviral activity against Ebolavirus. [5]

As reported in March 2009, Kenneth Palmer and coworkers modified the tobacco mosaic virus to incorporate the griffithsin gene and infected more than 9,300 tobacco plants. They were able to extract enough griffithsin to produce about 100,000 HIV microbicide doses from the leaves. [6]

Related Research Articles

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.

Lectin

Lectins are carbohydrate-binding proteins that are highly specific for sugar groups that are part of other molecules and so cause agglutination of particular cells or precipitation of glycoconjugates and polysaccharides. Lectins have a role in recognition at the cellular and molecular level and play numerous roles in biological recognition phenomena involving cells, carbohydrates, and proteins. Lectins also mediate attachment and binding of bacteria, viruses, and fungi to their intended targets.

Nelfinavir Antiretroviral drug

Nelfinavir is an antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV). Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is almost always used in combination with other antiretroviral drugs. Nelfinavir has been shown to treat SARS-coronavirus, and is being tested to treat COVID-19.

DC-SIGN

DC-SIGN also known as CD209 is a protein which in humans is encoded by the CD209 gene.

Envelope glycoprotein GP120 Glycoprotein exposed on the surface of the HIV virus

Envelope glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope. It was discovered by Professors Tun-Hou Lee and Myron "Max" Essex of the Harvard School of Public Health in 1988. The 120 in its name comes from its molecular weight of 120 kDa. Gp120 is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface receptors. These receptors are DC-SIGN, Heparan Sulfate Proteoglycan and a specific interaction with the CD4 receptor, particularly on helper T-cells. Binding to CD4 induces the start of a cascade of conformational changes in gp120 and gp41 that lead to the fusion of the viral membrane with the host cell membrane. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

Viral entry

Viral entry is the earliest stage of infection in the viral life cycle, as the virus comes into contact with the host cell and introduces viral material into the cell. The major steps involved in viral entry are shown below. Despite the variation among viruses, there are several shared generalities concerning viral entry.

Cyanovirin-N (CV-N) is a protein produced by the cyanobacterium Nostoc ellipsosporum that displays virucidal activity against several viruses, including human immunodeficiency virus (HIV). The virucidal activity of CV-N is mediated through specific high-affinity interactions with the viral surface envelope glycoproteins gp120 and gp41, as well as to high-mannose oligosaccharides found on the HIV envelope. In addition, CV-N is active against rhinoviruses, human parainfluenza virus, respiratory syncytial virus, and enteric viruses. The virucidal activity of CV-N against influenza virus is directed towards viral haemagglutinin. CV-N has a complex fold composed of a duplication of a tandem repeat of two homologous motifs comprising three-stranded beta-sheet and beta-hairpins.

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D.

Galectin

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine, which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding. There have been about 15 galectins discovered in mammals, encoded by the LGALS genes, which are numbered in a consecutive manner. Only galectin-1, -2, -3, -4, -7, -7B, -8, -9, -9B, 9C, -10, -12, -13, -14, and -16 have been identified in humans. Galectin-5 and -6 are found in rodents, whereas galectin-11 and -15 are uniquely found in sheep and goats. Members of the galectin family have also been discovered in other mammals, birds, amphibians, fish, nematodes, sponges, and some fungi. Unlike the majority of lectins they are not membrane bound, but soluble proteins with both intra- and extracellular functions. They have distinct but overlapping distributions but found primarily in the cytosol, nucleus, extracellular matrix or in circulation. Although many galectins must be secreted, they do not have a typical signal peptide required for classical secretion. The mechanism and reason for this non-classical secretion pathway is unknown.

Visna virus from the genus Lentivirus and subfamily Orthoretrovirinae, is a "prototype" retrovirus that causes encephalitis and chronic pneumonitis in sheep. It is known as visna when found in the brain, and maedi when infecting the lungs. Lifelong, persistent infections in sheep occur in the lungs, lymph nodes, spleen, joints, central nervous system, and mammary glands; The condition is sometimes known as "ovine progressive pneumonia" (OPP), particularly in the United States, or "Montana sheep disease". White blood cells of the monocyte/macrophage lineage are the main target of visna virus.

CLEC4M

C-type lectin domain family 4 member M is a protein that in humans is encoded by the CLEC4M gene. CLEC4M has also been designated as CD299.

GANAB

Neutral alpha-glucosidase AB is an enzyme that in humans is encoded by the GANAB gene.

<i>GBA2</i>

GBA2 is the gene that encodes the enzyme non-lysosomal glucosylceramidase in humans. It has glucosylceramidase activity.

Viral neuraminidase

Viral neuraminidase is a type of neuraminidase found on the surface of influenza viruses that enables the virus to be released from the host cell. Neuraminidases are enzymes that cleave sialic acid groups from glycoproteins. Neuraminidase inhibitors are antiviral agents that inhibit influenza viral neuraminidase activity and are of major importance in the control of influenza.

FGI-104

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus.

BanLec is a lectin from the jacalin-related lectin family isolated from the fruit of the bananas Musa acuminata and Musa balbisiana. BanLec is one of the predominant proteins in the pulp of ripe bananas and has binding specificity for mannose and mannose-containing oligosaccharides. A 2010 study reported that BanLec was a potent inhibitor of HIV replication.

CVNH domain

In molecular biology, the CVNH domain is a conserved protein domain. It is found in the sugar-binding antiviral protein cyanovirin-N (CVN) as well as proteins from filamentous ascomycetes and in the fern Ceratopteris richardii.

Jacalin-like lectin domain

In molecular biology, the jacalin-like lectin domain is a mannose-binding lectin domain with a beta-prism fold consisting of three 4-stranded beta-sheets, with an internal pseudo 3-fold symmetry. Some lectins in this group stimulate distinct T- and B-cell functions, such as Jacalin, which binds to the T-antigen and acts as an agglutinin. This domain is found in 1 to 6 copies in lectins. The domain is also found in the salt-stress induced protein from rice and an animal prostatic spermine-binding protein.

Scytonema varium is a cultured cyanobacterium of the genus Scytonema. It is one of many anti viral protein producing algae. In a similar manner to Cyanovirin-N from Nostoc Ellipsosporum and griffithsin from the red algae Griffithsia, Scytonema varium secretes the broad-spectrum antiviral protein scytovirin which can inactivate both the HIV virus, and Ebola virus, offering hope of treatment for many diseases with viral etiology (cause). It is currently being investigated as a topical microbicide for HIV prophylaxis.

Scytovirin is a 95-amino acid antiviral protein isolated from the cyanobacteria Scytonema varium. It has been cultured in E. coli and its structure investigated in detail. Scytovirin is thought to be produced by the bacteria to protect itself from viruses that might otherwise attack it, but as it has broad-spectrum antiviral activity against a range of enveloped viruses, scytovirin has also been found to be useful against a range of major human pathogens, most notably HIV / AIDS but also including SARS coronavirus and filoviruses such as Ebola virus and Marburg virus. While some lectins such as cyanovirin and Urtica dioica agglutinin are thought likely to be too allergenic to be used internally in humans, studies so far on scytovirin and griffithsin have not shown a similar level of immunogenicity. Scytovirin and griffithsin are currently being investigated as potential microbicides for topical use.

References

  1. Moulaei T, Shenoy SR, Giomarelli B, Thomas C, McMahon JB, Dauter Z, et al. (September 2010). "Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity". Structure. 18 (9): 1104–15. doi:10.1016/j.str.2010.05.016. PMC   3399781 . PMID   20826337.
  2. Mori T, O'Keefe BR, Sowder RC, Bringans S, Gardella R, Berg S, et al. (March 2005). "Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp". The Journal of Biological Chemistry. 280 (10): 9345–53. doi: 10.1074/jbc.M411122200 . PMID   15613479.
  3. Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, Palmer KE, et al. (August 2007). "Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide". Journal of Medical Primatology. 36 (4–5): 244–53. doi: 10.1111/j.1600-0684.2007.00242.x . PMID   17669213.
  4. O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, et al. (March 2010). "Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae". Journal of Virology. 84 (5): 2511–21. doi:10.1128/JVI.02322-09. PMC   2820936 . PMID   20032190.
  5. Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, et al. (2014). "Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models". Antimicrobial Agents and Chemotherapy. 58 (1): 120–7. doi:10.1128/AAC.01407-13. PMC   3910741 . PMID   24145548.
  6. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, et al. (April 2009). "Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component". Proceedings of the National Academy of Sciences of the United States of America. 106 (15): 6099–104. doi:10.1073/pnas.0901506106. PMC   2662964 . PMID   19332801.